Guggenheim Cuts Bruker (NASDAQ:BRKR) Price Target to $50.00

Bruker (NASDAQ:BRKR) had its price objective reduced by Guggenheim from $58.00 to $50.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

BRKR has been the subject of several other reports. UBS Group restated a “neutral” rating and set a $49.00 price objective on shares of Bruker in a research report on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on Bruker in a research report on Thursday, February 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Friday, March 27th. Bank of America upped their price objective on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Barclays decreased their price objective on Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $49.77.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $36.08 on Monday. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company’s 50-day moving average price is $39.18 and its 200 day moving average price is $41.31. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of -240.53, a PEG ratio of 2.16 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The business had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s payout ratio is currently -133.33%.

Insider Buying and Selling

In related news, VP Mark Munch sold 7,000 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 11,000 shares of company stock valued at $554,280 in the last ninety days. Corporate insiders own 27.30% of the company’s stock.

Institutional Trading of Bruker

Hedge funds have recently added to or reduced their stakes in the business. Orbis Allan Gray Ltd increased its position in Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after purchasing an additional 761,258 shares in the last quarter. State Street Corp lifted its position in Bruker by 2.5% during the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after buying an additional 91,706 shares in the last quarter. AQR Capital Management LLC grew its stake in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the period. Sculptor Capital LP grew its stake in Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after buying an additional 476,363 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after acquiring an additional 336,026 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.